Anton Buzdin (AB) graduated from Moscow State University and defended PhD thesis in molecular biology at Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry. Since 2005, AB runs several research laboratories. AB also worked as CEO of several international biotech and biomed companies. AB authored 153 research papers and patent applications and discovered multiple molecular markers of human cancer. He pioneered bioinformatic quantitative analysis of molecular pathways and developed several specialized algorithms and software packages, applied to improve designation of proper target or chemotherapy drugs to the patients. He authored several techniques in molecular biology for differential analysis of gene expression and of epigenetic landmarks. In 2017, AB participated in the Y Combinator startup accelerator program. AB heads 19 international employees and runs fundamental and commercial projects on molecular oncology and clinical bioinformatics at Omicsway and academic institutes.